Articles published by Baudax Bio, Inc.
 
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces Pricing of $4 Million Public Offering
    
   April 26, 2023
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces Positive Top-Line Final Results From Phase 2 Randomized Clinical Trial of BX1000
    
   April 25, 2023
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio to Host Key Opinion Leader Webinar to Discuss Results of Phase 2 BX1000 Trial
    
   April 24, 2023
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces Positive Results from 2nd Interim Analysis of Phase 2 Randomized Trial for BX1000
    
   March 27, 2023
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Reports 2022 Fourth Quarter and Annual Financial Results and Provides Business Update
    
   February 23, 2023
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
    
   January 24, 2023
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
    
   December 08, 2022
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces Closing of $5 Million Public Offering
    
   December 06, 2022
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces Pricing of $5 Million Public Offering
    
   December 02, 2022
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   
    Baudax Bio Announces 1-for-40 Reverse Stock Split
    
   November 30, 2022
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
    
   From Baudax Bio, Inc.
   Via GlobeNewswire
    Tickers
      BXRX
    
   
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.